STA Research assigns Mountain Valley MD Holdings Inc. with a Speculative Buy rating, and a 12 month target price forecast of .50 cents per share.
Based on the Mountain Valley MD Holdings Inc. stock (mvmd stock price) forecasts from 1 analyst, the average analyst target price for Mountain Valley MD Holdings Inc. (mvmd stock price) is $.50 over the next 12 months. Mountain Valley MD Holdings Inc.’s (mvmd stock price) average analyst rating is Speculative Buy. Stock Target Advisor’s own stock analysis of Mountain Valley MD Holdings Inc. is Very Bearish, which is based on 0 positive signals and 3 negative signals. At the last closing, Mountain Valley MD Holdings Inc.’s stock price was CAD 0.07. Mountain Valley MD Holdings Inc.’s stock price has changed by +0.00% over the past week, -0.01% over the past month and -82.28% over the last year.
A health and wellness business is run by Mountain Valley MD Holdings Inc. through its subsidiary, Mountain Valley MD Inc. The business works with third parties in the pharmaceutical, vaccine, and nutraceutical industries to implement and licence its technology. For the human parasitic, therapeutic, animal parasitic, oncology, vaccination, human pharmaceutical, human nutraceutical, and insulin drug sectors, it offers Quicksome oral drug formulation and delivery technologies, Quicksol solubility formulation technology, and dosage sparing adjuvant. The corporate headquarters of Mountain Valley MD Holdings Inc. are in Concord, Canada. Contact information: 260 Edgeley Boulevard, Concord, Ontario, Canada, L4K 3Y4.
What we like:
There is no fundamental attribute that we can detect on the stock that would warrant a positive outlook. The stock is a pure speculative play!
What we don’t like:
The total returns for this company are volatile and above the median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cash flow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.